Mink Therapeutics logo

Mink Therapeutics Share Price Today

(NASDAQ: INKT)

Mink Therapeutics share price is $7.02 & ₹600.20 as on 9 May 2025, 2.30 'hrs' IST

$7.02

-0.36

(-4.88%)

Market is closed - opens 7 PM, 09 May 2025

View live Mink Therapeutics share price in Dollar and Rupees. Guide to invest in Mink Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Mink Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Mink Therapeutics share price movements

  • Today's Low: $7.02
    Today's High: $7.02

    Day's Volatility :0.0%

  • 52 Weeks Low: $4.56
    52 Weeks High: $13.79

    52 Weeks Volatility :66.93%

Mink Therapeutics (INKT) Returns

PeriodMink Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-37.27%
-7.6%
0.0%
6 Months
-6.41%
-9.9%
0.0%
1 Year
-21.94%
-5.6%
0.0%
3 Years
-53.82%
7.0%
0.4%

Mink Therapeutics (INKT) Key Statistics

in dollars & INR

Previous Close
$7.38
Open
$7.02
Today's High
$7.02
Today's Low
$7.02
Market Capitalization
$30.1M
Today's Volume
$868.0
52 Week High
$13.79
52 Week Low
$4.5601
Revenue TTM
$0.0
EBITDA
$-11.1M
Earnings Per Share (EPS)
$-2.86
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1238.98%

How to invest in Mink Therapeutics Stock (INKT) from India?

It is very easy for Indian residents to invest directly in Mink Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mink Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Mink Therapeutics or INKT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mink Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mink Therapeutics shares which would translate to 0.122 fractional shares of Mink Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Mink Therapeutics, in just a few clicks!

Returns in Mink Therapeutics (INKT) for Indian investors in Rupees

The Mink Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Mink Therapeutics investment value today

Current value as on today

₹80,490

Returns

₹19,510

(-19.51%)

Returns from Mink Therapeutics Stock

₹21,913 (-21.91%)

Dollar Returns

₹2,404 (+2.4%)

Indian investors sentiment towards Mink Therapeutics (INKT)

200%

Period: Apr 8, 2025 to May 8, 2025. Change in 30 Days versus previous period

Search interest for Mink Therapeutics Stock from India on INDmoney has increased by 200% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Mink Therapeutics

    Analyst Recommendation on Mink Therapeutics

    Rating
    Trend

    Buy

      90%Buy

      10%Hold

      0%Sell

    Based on 10 Wall street analysts offering stock ratings for Mink Therapeutics(by analysts ranked 0 to 5 stars)

    Analyst Forecast on Mink Therapeutics Stock (INKT)

    What analysts predicted

    Upside of 588.51%

    Target:

    $48.33

    Current:

    $7.02

    Insights on Mink Therapeutics Stock (Ticker Symbol: INKT)

    • Price Movement

      In the last 3 months, INKT stock has moved down by -34.0%
    • Decreasing Revenue

      Revenue is down for the last 2 quarters, 11.70B → -11.70B (in $), with an average decrease of 200.0% per quarter
    • Decreasing Net Profit

      Netprofit is down for the last 2 quarters, -1.80M → -2.46M (in $), with an average decrease of 36.3% per quarter
    • INKT vs ALNY (1 yr)

      In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.8% return, outperforming this stock by 100.7%
    • INKT vs ALNY (3 yr)

      In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 125.8% return, outperforming this stock by 183.9%

    Mink Therapeutics Technicals Summary

    Sell

    Neutral

    Buy

    Mink Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

    Mink Therapeutics (INKT) Vs Peers

    Returns
    Ratio's
    Overview
    Company Name1 Month6 Month1 Year3 Years5 Years
    Mink Therapeutics, Inc. logo
    -7.51%
    -6.41%
    -21.94%
    -53.82%
    -94.15%
    Regeneron Pharmaceuticals, Inc. logo
    -2.78%
    -33.93%
    -43.46%
    -11.02%
    -4.67%
    Beone Medicines Ltd logo
    12.71%
    14.87%
    39.96%
    64.27%
    44.57%
    Vertex Pharmaceuticals Incorporated logo
    -9.84%
    -16.72%
    2.7%
    79.18%
    50.84%
    Alnylam Pharmaceuticals, Inc. logo
    13.72%
    -6.7%
    71.0%
    101.94%
    81.73%

    About Mink Therapeutics

    MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
    Organization
    Mink Therapeutics
    Employees
    23
    CEO
    Dr. Jennifer S. Buell Ph.D.
    Industry
    Services

    Management People of Mink Therapeutics

    NameTitle
    Dr. Garo H. Armen Ph.D.
    Executive Chairman
    Dr. Jennifer S. Buell Ph.D.
    President, CEO & Director
    Ms. Christine M. Klaskin
    Treasurer and Principal Financial & Accounting Officer
    Ms. Eleni Chantzoura Ph.D.
    Director & Head of Discovery

    Important FAQs about investing in INKT Stock from India :

    What is Mink Therapeutics share price today?

    Mink Therapeutics share price today stands at $7.02, Open: $7.02 ; Previous Close: $7.38 ; High: $7.02 ; Low: $7.02 ; 52 Week High: $13.79 ; 52 Week Low: $4.56.

    The stock opens at $7.02, after a previous close of $7.38. The stock reached a daily high of $7.02 and a low of $7.02, with a 52-week high of $13.79 and a 52-week low of $4.56.

    Can Indians buy Mink Therapeutics shares?

    Yes, Indians can invest in the Mink Therapeutics (INKT) from India.

    With INDmoney, you can buy Mink Therapeutics at 0 brokerage. The step-by-step process is as follows:

    • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
    • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
    • Once funds are transferred successfully, you can buy Mink Therapeutics at zero transaction cost.

    How can I buy Mink Therapeutics shares from India?

    It is very easy to buy Mink Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

    Can Fractional shares of Mink Therapeutics (INKT) be purchased?

    Yes, you can buy fractional shares of Mink Therapeutics with INDmoney app.

    What are the documents required to start investing in Mink Therapeutics stocks?

    To start investing in Mink Therapeutics, You will need the following documents:

    • Proof of Identification (PAN, Aadhaar etc)
    • Proof of address (Aadhaar, Voter ID etc)

    These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

    What are today’s High and Low prices of Mink Therapeutics Stock (INKT)?

    Today’s highest price of Mink Therapeutics (INKT) is $7.02.

    Today’s lowest price of Mink Therapeutics (INKT) is $7.02.

    What is today's market capitalisation of Mink Therapeutics?

    Today's market capitalisation of Mink Therapeutics INKT is 30.1M

    What is the 52 Week High and Low Range of Mink Therapeutics Stock (INKT)?

    • 52 Week High

      $13.79

    • 52 Week Low

      $4.56

    What are the historical returns of Mink Therapeutics (INKT)?

    • 1 Month Returns

      -7.51%

    • 3 Months Returns

      -6.41%

    • 1 Year Returns

      -21.94%

    • 5 Years Returns

      -94.15%

    Who is the Chief Executive Officer (CEO) of Mink Therapeutics ?

    Dr. Jennifer S. Buell Ph.D. is the current Chief Executive Officer (CEO) of Mink Therapeutics.